Drugs

pp 1–9 | Cite as

Management of Embolic Stroke of Undetermined Source (ESUS)

  • Tobias Geisler
  • Annerose Mengel
  • Ulf Ziemann
  • Sven Poli
Review Article
  • 78 Downloads

Abstract

According to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification, embolic stroke of undetermined source (ESUS) has refined the old definition of cryptogenic stroke. More sophisticated criteria and a well-defined diagnostic workup point out the embolic nature of this disease. Because ESUS is associated with a high stroke recurrence, a clear risk prediction and management is of utmost importance to improve prognosis. To date, standard pharmacotherapy consists of antiplatelet drugs and statins. This review attempts to provide an overview on the diagnostic criteria, prognosis, and current clinical trials evaluating the value of direct oral anticoagulants for secondary prevention after ESUS.

Notes

Compliance with Ethical Standards

Funding

No external funding was used in the preparation of this manuscript.

Conflicts of interest

Tobias Geisler reports personal fees from AstraZeneca, Boehringer Ingelheim, Pfizer, and MSD; grants and personal fees from Bayer Healthcare, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, and The Medicines Company; and grants from Siemens Healthcare and Spartan Bioscience, outside the submitted work. Annerose Mengel has no conflicts of interest relevant to the presented work. Ulf Ziemann has received speaker honoraria and/or travel compensation from Bayer Vital GmbH, Biogen Idec GmbH, Bristol Myers Squibb GmbH, Medtronic GmbH, and Pfizer GmbH; and grants from Biogen Idec GmbH, Servier, and Janssen Pharmaceuticals NV. He serves on the advisory board of CorTec GmbH. None of the above are related to the submitted work. Sven Poli has received speaker’s honoraria and consulting honoraria from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo and Werfen; reimbursement for congress traveling and accommodation from Bayer and Boehringer Ingelheim; and research support from Bristol-Myers Squibb/Pfizer, Boehringer-Ingelheim, Daiichi Sankyo and Helena Laboratories. None of the above are related to the submitted work.

References

  1. 1.
    Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, Cryptogenic Stroke/ESUS International Working Group, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13:429–38.CrossRefPubMedGoogle Scholar
  2. 2.
    Perera KS, Vanassche T, Bosch J, Giruparajah M, Swaminathan B, Mattina KR, ESUS Global Registry Investigators, et al. Embolic strokes of undetermined source: prevalence and patient features in the ESUS Global Registry. Int J Stroke. 2016;11(5):526–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke of undetermined source: a systematic review and clinical update. Stroke. 2017;48(4):867–72.CrossRefPubMedGoogle Scholar
  4. 4.
    Martinez-Majander N, Aarnio K, Pirinen J, Lumikari T, Nieminen T, Lehto M, et al. Embolic strokes of undetermined source in young adults: baseline characteristics and long-term outcome. Eur J Neurol. 2018;25(3):535–41.CrossRefPubMedGoogle Scholar
  5. 5.
    Perera KS, Swaminathan B, Veltkamp R, Arauz A, Ameriso S, Marti-Fabregas J, et al. Frequency and features of embolic stroke of undetermined source in young adults. Eur Stroke J. 2018;3(2):110–6.CrossRefGoogle Scholar
  6. 6.
    Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke. 2001;32(11):2559–66.CrossRefPubMedGoogle Scholar
  7. 7.
    Ntaios G, Vemmos K, Lip GY, Koroboki E, Manios E, Vemmou A, et al. Risk stratification for recurrence and mortality in embolic stroke of undetermined source. Stroke. 2016;47(9):2278–85.CrossRefPubMedGoogle Scholar
  8. 8.
    Bal S, Patel SK, Almekhlafi M, Modi J, Demchuk AM, Coutts SB. High rate of magnetic resonance imaging stroke recurrence in cryptogenic transient ischemic attack and minor stroke patients. Stroke. 2012;43(12):3387–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Kang DW, Lattimore SU, Latour LL, Warach S. Silent ischemic lesion recurrence on magnetic resonance imaging predicts subsequent clinical vascular events. Arch Neurol. 2006;63(12):1730–3.CrossRefPubMedGoogle Scholar
  10. 10.
    Gioia LC, Tollard É, Dubuc V, Lanthier S, Deschaintre Y, Chagnon M, et al. Silent ischemic lesions in young adults with first stroke are associated with recurrent stroke. Neurology. 2012;79(12):1208–14.CrossRefPubMedGoogle Scholar
  11. 11.
    Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348(13):1215–22.CrossRefPubMedGoogle Scholar
  12. 12.
    Friberg L, Rosenqvist M, Lindgren A, Terént A, Norrving B, Asplund K. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke. 2014;45(9):2599–605.CrossRefPubMedGoogle Scholar
  13. 13.
    Seet RC, Zhang Y, Wijdicks EF, Rabinstein AA. Relationship between chronic atrial fibrillation and worse outcomes in stroke patients after intravenous thrombolysis. Arch Neurol. 2011;68(11):1454–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Yoo J, Song D, Baek JH, Kim YD, Nam HS, Hong GR, et al. Poor outcome of stroke patients with atrial fibrillation in the presence of coexisting spontaneous echo contrast. Stroke. 2016;47(7):1920–2.CrossRefPubMedGoogle Scholar
  15. 15.
    Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, CRYSTAL AF Investigators, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370(26):2478–86.CrossRefPubMedGoogle Scholar
  16. 16.
    Gladstone DJ, Spring M, Dorian P, et al. Cryptogenic stroke and atrial fibrillation. N Engl J Med. 2014;370:2467–77.CrossRefPubMedGoogle Scholar
  17. 17.
    Sposato LA, Cipriano LE, Saposnik G, Ruíz Vargas E, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 2015;14(4):377–87.CrossRefPubMedGoogle Scholar
  18. 18.
    Wachter R, Gröschel K, Gelbrich G, Hamann GF, Kermer P, Liman J, Find-AF(randomised) Investigators and Coordinators, et al. Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AFRANDOMISED): an open-label randomised controlled trial. Lancet Neurol. 2017;16(4):282–90.CrossRefPubMedGoogle Scholar
  19. 19.
    Haeusler KG, Kirchhof P, Heuschmann PU, Laufs U, Busse O, Kunze C, et al. Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS): rationale and design of a prospective randomized multicenter study. Am Heart J. 2016;172:19–25.CrossRefPubMedGoogle Scholar
  20. 20.
    Thijs VN, Brachmann J, Morillo CA, Passman RS, Sanna T, Bernstein RA, et al. Predictors for atrial fibrillation detection after cryptogenic stroke: results from CRYSTAL AF. Neurology. 2016;86(3):261–9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Hoshino T, Nagao T, Shiga T, Maruyama K, Toi S, Mizuno S, et al. Prolonged QTc interval predicts poststroke paroxysmal atrial fibrillation. Stroke. 2015;46(1):71–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Gladstone DJ, Dorian P, Spring M, Panzov V, Mamdani M, Healey JS, et al. Atrial premature beats predict atrial fibrillation in cryptogenic stroke: results from the EMBRACE trial. Stroke. 2015;46(4):936–41.CrossRefPubMedGoogle Scholar
  23. 23.
    Poli S, Diedler J, Härtig F, Götz N, Bauer A, Sachse T, et al. Insertable cardiac monitors after cryptogenic stroke—a risk factor based approach to enhance the detection rate for paroxysmal atrial fibrillation. Eur J Neurol. 2016;23(2):375–81.CrossRefPubMedGoogle Scholar
  24. 24.
    Kamel H, O’Neal WT, Okin PM, Loehr LR, Alonso A, Soliman EZ. Electrocardiographic left atrial abnormality and stroke subtype in the atherosclerosis risk in communities study. Ann Neurol. 2015;78(5):670–8.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Yaghi S, Song C, Gray WA, Furie KL, Elkind MS, Kamel H. Left atrial appendage function and stroke risk. Stroke. 2015;46(12):3554–9.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Van Gelder IC, Healey JS, Crijns HJGM, Wang J, Hohnloser SH, Gold MR, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J. 2017;38(17):1339–44.CrossRefPubMedGoogle Scholar
  27. 27.
    Geisler T, Poli S, Meisner C, Schreieck J, Zuern CS, Nägele T, et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): rationale and study design. Int J Stroke. 2017;12(9):985–90.CrossRefPubMedGoogle Scholar
  28. 28.
    SPS3 Investigators, Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367(9):817–25.Google Scholar
  29. 29.
    Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(1):11–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Pan Y, Jing J, Chen W, Meng X, Li H, Zhao X, et al. CHANCE investigators. Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: time course analysis of CHANCE. Neurology. 2017;88(20):1906–11.CrossRefPubMedGoogle Scholar
  32. 32.
    Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, SOCRATES Steering Committee and Investigators, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375(1):35–43.CrossRefPubMedGoogle Scholar
  33. 33.
    Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, SOCRATES Steering Committee and Investigators, et al. Ticagrelor versus aspirin in acute embolic stroke of undetermined source. Stroke. 2017;48(9):2480–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Kim SK, Yoon W, Kim TS, Kim HS, Heo TW, Park MS. Histologic analysis of retrieved clots in acute ischemic stroke: correlation with stroke etiology and gradient-echo MRI. AJNR. 2015;36(9):1756–62.CrossRefPubMedGoogle Scholar
  35. 35.
    Sacco RL, Prabhakaran S, Thompson JL, Murphy A, Sciacca RR, Levin B, WARSS Investigators, et al. Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin-Aspirin Recurrent Stroke Study. Cerebrovasc Dis. 2006;22(1):4–12.CrossRefPubMedGoogle Scholar
  36. 36.
    Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.CrossRefPubMedGoogle Scholar
  37. 37.
    Ntaios G, Papavasileiou V, Makaritsis K, Vemmos K, Michel P, Lip GYH. Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-k antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 2017;48(9):2494–503.CrossRefPubMedGoogle Scholar
  38. 38.
    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.CrossRefPubMedGoogle Scholar
  39. 39.
    Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, AVERROES Steering Committee and Investigators, et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol. 2012;11(3):225–31.CrossRefPubMedGoogle Scholar
  40. 40.
    Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, ROCKET AF Steering Committee Investigators, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012;11(4):315–22.CrossRefPubMedGoogle Scholar
  41. 41.
    Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, RE-LY study group, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010;9(12):1157–63.CrossRefPubMedGoogle Scholar
  42. 42.
    Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, ARISTOTLE Committees and Investigators, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012;11(6):503–11.CrossRefPubMedGoogle Scholar
  43. 43.
    Rost NS, Giugliano RP, Ruff CT, Murphy SA, Crompton AE, Norden AD, ENGAGE AF-TIMI 48 Investigators, et al. Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (Effective anticoagulation with factor Xa next generation in atrial fibrillation thrombolysis in myocardial infarction 48). Stroke. 2016;47(8):2075–82.CrossRefPubMedGoogle Scholar
  44. 44.
    Diener HC, Easton JD, Granger CB, Cronin L, Duffy C, Cotton D, RE-SPECT ESUS Investigators, et al. Design of randomized, double-blind, evaluation in secondary stroke prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). Int J Stroke. 2015;10(8):1309–12.CrossRefPubMedGoogle Scholar
  45. 45.
    Hart RG, Sharma M, Mundl H, Shoamanesh A, Kasner SE, Berkowitz SD, et al. Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: design of the NAVIGATE ESUS randomized trial. Eur Stroke J. 2016;1(3):146–54.CrossRefGoogle Scholar
  46. 46.
    O’Donnell MJ, Eikelboom JW, Yusuf S, Diener HC, Hart RG, Smith EE, et al. Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. Am Heart J. 2016;178:145–50.CrossRefPubMedGoogle Scholar
  47. 47.
    Kent DM, Dahabreh IJ, Ruthazer R, Furlan AJ, Weimar C, Serena J, et al. Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis. Eur Heart J. 2015;36(35):2381–9.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160–236.CrossRefPubMedGoogle Scholar
  49. 49.
    Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, Patent Foramen Ovale and Atrial Septal Aneurysm Study Group, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med. 2001;345(24):1740–6.CrossRefPubMedGoogle Scholar
  50. 50.
    Mas JL, Derumeaux G, Guillon B, CLOSE Investigators. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377(11):1011–21.CrossRefPubMedGoogle Scholar
  51. 51.
    Søndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, Gore REDUCE Clinical Study Investigators, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377(11):1033–42.CrossRefPubMedGoogle Scholar
  52. 52.
    Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, RESPECT Investigators, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377(11):1022–32.CrossRefPubMedGoogle Scholar
  53. 53.
    Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Wolf ME, Hennerici MG. The ASCOD phenotyping of ischemic stroke (updated ASCO phenotyping). Cerebrovasc Dis. 2013;36:1–5.CrossRefPubMedGoogle Scholar
  54. 54.
    Ay H, Benner T, Arsava EM, Furie KL, Singhal AB, Jensen MB, et al. A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. Stroke. 2007;38:2979–84.CrossRefPubMedGoogle Scholar
  55. 55.
    Eckerle B, Massaro A. Lumpers or splitters: evaluation and management of embolic stroke of undetermined source. Neurology. 2016;87:972–3.CrossRefPubMedGoogle Scholar
  56. 56.
    Dennis M. Embolic stroke of undetermined source: a therapeutic target? Lancet Neurol. 2014;13:344–6.CrossRefPubMedGoogle Scholar
  57. 57.
    Katsanos AH, Bhole R, Frogoudaki A, Giannopoulos S, Goyal N, Vrettou AR, et al. The value of transesophageal echocardiography for embolic strokes of undetermined source. Neurology. 2016;87:988–95.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Tobias Geisler
    • 1
  • Annerose Mengel
    • 2
  • Ulf Ziemann
    • 2
  • Sven Poli
    • 2
  1. 1.Department of CardiologyUniversity Hospital TübingenTübingenGermany
  2. 2.Department of Neurology and StrokeUniversity Hospital TübingenTübingenGermany

Personalised recommendations